FeNO by NIOX® USA
Chelsea Mundy is an experienced professional with a diverse background in healthcare and business management. Currently serving as a Territory Business Representative at Circassia USA since June 2019, Chelsea has also held various roles at ADP, including District Manager and Associate District Manager since July 2016. Chelsea earned an MBA with a concentration in Healthcare Administration from Methodist University, where the capstone project focused on the benefits of implementing a wellness program. Previous experience includes roles as a Billing and Insurance Intern at Physicians East and a Patient Experience Intern at Cone Health. Chelsea holds a degree in Health Service Management from East Carolina University.
This person is not in the org chart
This person is not in any teams
FeNO by NIOX® USA
NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma. NIOX VERO® provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, with a simple touch screen interface and intuitive design, and can be used in a variety of settings, including clinics, hospitals, and primary care settings. The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals. Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive1 tool to help them better diagnose and manage asthma. References: 1. Alving K et al. Pulm Ther. 2017;3:207-218. 2. Gao J et al. Allergy, Asthma & Clinical Immunology. 2018;1 3. Busse WW et al. Lancet Respir Med. 2021;9(10):1165-1173. 4. Menzies-Gow A et al. Eur Respir J. 2020;55(3):1901633. 5. NIOX® Data on File. MKT-DOF-006. 2023.